Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation

NCT07237100 is registered in ClinicalTrials.gov with Kevin Kim, MD as lead sponsor.

NCT NCT07237100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07237100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation
Lead sponsor
Kevin Kim, MD
Phase
Phase 2
Overall status
Recruiting
Start date
October 13, 2025
Completion date
October 13, 2030
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable melanoma, metastatic melanoma